19 withdrawn. 19 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 19 | Withdrawn 19 |
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mood Disorders in Head and Neck Cancer Patients Venlafaxine - Depressive Disorder, Head and Neck Cancer | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2024-01-05 | 2025-02-04 | |
| VA Aripiprazole vs Esketamine for Treatment Resistant Depression Esketamine, Aripiprazole - Depressive Disorder, Major | Phase 4 | Withdrawn | VA Office of Research and Development | 2023-10-27 | 2024-01-05 | |
| Preoperative Ketamine and Perioperative Depression Ketamine Group, Midazolam injection - Depressive Disorder | Phase 4 | Withdrawn | Northwestern University | 2022-09-01 | 2023-02-06 | |
| Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety Brexpiprazole - Major Depressive Disorder (MDD) | Phase 4 | Withdrawn | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-08-29 | 2023-01-30 | |
| Cannabidiol for Treatment Resistant Depression Active study drug ( oral CBD), matching placebo - Treatment Resistant Depression | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2021-07-01 | 2021-07-19 | |
| Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram Sertraline, Escitalopram - Major Depressive Disorder | Phase 4 | Withdrawn | Alto Neuroscience | 2020-10-15 | 2020-10-19 | |
| Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion Duloxetine, Bupropion - Major Depressive Disorder | Phase 4 | Withdrawn | Alto Neuroscience | 2020-10-15 | 2020-10-19 | |
| A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone) Brexanolone - Postpartum Depression | Phase 4 | Withdrawn | Sage Therapeutics | 2020-02-01 | 2020-08-18 | |
| EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders EnBrace HR Softgel - Premenstrual Syndrome, Premenstrual Dysphoric Disorder | Phase 4 | Withdrawn | Massachusetts General Hospital | 2019-11-01 | 2020-01-02 | |
| Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes Vortioxetine - Type2 Diabetes, Major Depressive Disorder | Phase 4 | Withdrawn | Todd Doyle | 2019-07-01 | 2022-11-29 | |
| Creatine for Treatment of Depression Associated With Type 2 Diabetes Creatine Monohydrate - Major Depressive Disorder | Phase 4 | Withdrawn | University of Utah | 2017-08-01 | 2024-06-11 | |
| Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients Paroxetine CR - Depressive Disorder | Phase 4 | Withdrawn | GlaxoSmithKline | 2014-01-01 | 2014-07-16 | |
| A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults Aripiprazole, Bupropion, Problem Solving Therapy - Major Depressive Disorder, Dysthymic Disorder | Phase 4 | Withdrawn | New York State Psychiatric Institute | 2013-08-01 | 2019-04-18 | |
| The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives Vilazodone, Citalopram - Major Depressive Disorder, Anxiety | Phase 4 | Withdrawn | Massachusetts General Hospital | 2013-04-01 | 2016-11-08 | |
| Creatine Augmentation in Veterans With SSRI-Resistant Major Depression Creatine - Major Depressive Disorder | Phase 4 | Withdrawn | University of Utah | 2012-09-01 | 2016-08-15 | |
| Lithium Versus Paroxetine in Major Depression Lithium, Paroxetine - Major Depressive Disorder | Phase 4 | Withdrawn | Nova Scotia Health Authority | 2011-09-01 | 2024-09-19 | |
| Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder Effexor XR, Effexor XR discontinue - Major Depressive Disorder | Phase 4 | Withdrawn | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-04-01 | 2021-08-20 | |
| Ketamine Frequency Treatment for Major Depressive Disorder Ketamine, Ketamine/Saline - Treatment Resistant Depression | Phase 4 | Withdrawn | Essentia Health | 2008-03-01 | 2011-06-06 | |
| Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment Risperidone - Treatment Resistant Depression | Phase 4 | Withdrawn | Vanderbilt University Medical Center | 2004-05-01 | 2017-04-04 |
Depressive Disorder, Major (11) · Depression (3) · Depressive Disorder, Treatment-Resistant (3) · Diabetes Mellitus, Type 2 (2) · Anxiety Disorders (1) · Bipolar Disorder (1) · Depression, Postpartum (1) · Diabetes Mellitus (1) · Dysthymic Disorder (1) · Head and Neck Neoplasms (1) · Premenstrual Dysphoric Disorder (1) · Premenstrual Syndrome (1)
Mental Disorders (19) · Mood Disorders (19) · Behavior (3) · Behavioral Symptoms (3) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Bipolar and Related Disorders (1) · Diabetes Mellitus (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Menstruation Disturbances (1) · Neoplasms (1) · Neoplasms by Site (1)
Ketamine (3) · Aripiprazole (2) · Bupropion (2) · Creatine (2) · Venlafaxine Hydrochloride (2) · Citalopram (1) · Dexetimide (1) · Duloxetine Hydrochloride (1) · Escitalopram (1) · Esketamine (1) · Lithium (1) · Lithium Carbonate (1) · Midazolam (1) · Paroxetine (1) · Risperidone (1)
Alto Neuroscience (2) · Massachusetts General Hospital (2) · University of Alabama at Birmingham (2) · University of Utah (2) · Essentia Health (1) · GlaxoSmithKline (1) · New York State Psychiatric Institute (1) · Northwestern University (1) · Nova Scotia Health Authority (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Sage Therapeutics (1) · Todd Doyle (1) · VA Office of Research and Development (1) · Vanderbilt University Medical Center (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (9) · Canada (1)
Corey Keller, MD, PhD (2) · Perry F Renshaw, MD, PhD, MBA (2) · Bret Rutherford, MD (1) · Charles Hogue, MD (1) · Claire O'Donovan, MD, FRCPC (1) · Jessica Grayson, MD (1) · Marlene P Freeman, MD (1) · Matthew Macaluso, D.O. (1) · Michael E Henry, MD (1) · Micheal Messer, MD (1) · Ronald M Salomon, MD (1) · Somaia Mohamed, PhD (1) · Todd Doyle, PhD (1)
R44MH123373 (1)